Devyn Smith
Chief Executive Officer Arbor Biotechnologies
Seminars
Wednesday 30th September 2026
Fireside Chat: Transitioning Gene Editing Therapeutics from Bespoke Treatments to Platform Approaches for Broader Disease Indications & Commercial Sustainability
9:00 am
- Identifying strategic, regulatory, and technical barriers limiting gene editing therapeutics to rare, single-patient applications and exploring pathways to expand into larger patient populations
- Examining how industry leaders are navigating manufacturing challenges, clinical development efficiency, and regulatory alignment to make genome editing commercially viable across multiple indications
- Discussing the organizational capabilities, investment priorities, and platform design decisions required to transition from boutique therapies to scalable, multi-disease treatment models
